Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Eosinophilic Gastroenteritis.

Current treatment options in gastroenterology

Caldwell JH.
PMID: 11792233
Curr Treat Options Gastroenterol. 2002 Feb;5(1):9-16. doi: 10.1007/s11938-002-0002-5.

There are no evidence-based studies of the treatment of patients with eosinophilic gastroenteritis. Treatment decisions depend on experience gained from observations linking causative entities, principal clinical manifestations, and anticipated natural history of the disease. Because clinical symptoms and organ...

Cite
Caldwell JH. Eosinophilic Gastroenteritis. Curr Treat Options Gastroenterol. 2002;5(1):9-16doi: 10.1007/s11938-002-0002-5.
Caldwell, J. H. (2002). Eosinophilic Gastroenteritis. Current treatment options in gastroenterology, 5(1), 9-16. https://doi.org/10.1007/s11938-002-0002-5
Caldwell, James H.. "Eosinophilic Gastroenteritis." Current treatment options in gastroenterology vol. 5,1 (2002): 9-16. doi: https://doi.org/10.1007/s11938-002-0002-5
Caldwell JH. Eosinophilic Gastroenteritis. Curr Treat Options Gastroenterol. 2002 Feb;5(1):9-16. doi: 10.1007/s11938-002-0002-5. PMID: 11792233.
Copy Download .nbib Format: NLM
Cromolyn sodium: a new drug for the treatment of atopic allergic disorders.

The Western journal of medicine

Siegel S.
PMID: 18747413
West J Med. 1974 Jul;121(1):59.

No abstract available.

Cite
Siegel S. Cromolyn sodium: a new drug for the treatment of atopic allergic disorders. West J Med. 1974;121(1):59
Siegel, S. (1974). Cromolyn sodium: a new drug for the treatment of atopic allergic disorders. The Western journal of medicine, 121(1), 59.
Siegel, S. "Cromolyn sodium: a new drug for the treatment of atopic allergic disorders." The Western journal of medicine vol. 121,1 (1974): 59.
Siegel S. Cromolyn sodium: a new drug for the treatment of atopic allergic disorders. West J Med. 1974 Jul;121(1):59. PMID: 18747413; PMCID: PMC1129492.
Copy Download .nbib Format: NLM
Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent.

Iranian journal of pharmaceutical research : IJPR

Mombeini T, Zahedpoure-Anaraki MR, Dehpour AR.
PMID: 24250478
Iran J Pharm Res. 2012;11(2):549-57.

Cromolyn sodium, a mast cell stabilizing agent, provides an immediate protective effect against the exercise-induced bronchoconstriction while being used before the exercise. However, cromolyn is ineffective in reversing asthmatic bronchospasm; it is used as a maintenance therapy and has...

Cite
Mombeini T, Zahedpoure-Anaraki MR, Dehpour AR. Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent. Iran J Pharm Res. 2012;11(2):549-57
Mombeini, T., Zahedpoure-Anaraki, M. R., & Dehpour, A. R. (2012). Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent. Iranian journal of pharmaceutical research : IJPR, 11(2), 549-57.
Mombeini, Tajmah, et al. "Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent." Iranian journal of pharmaceutical research : IJPR vol. 11,2 (2012): 549-57.
Mombeini T, Zahedpoure-Anaraki MR, Dehpour AR. Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent. Iran J Pharm Res. 2012;11(2):549-57. PMID: 24250478; PMCID: PMC3832161.
Copy Download .nbib Format: NLM
A pharmacological approach assessing the role of mast cells in insulin infusion site inflammation.

Drug delivery and translational research

Kesserwan S, Mao L, Sharafieh R, Kreutzer DL, Klueh U.
PMID: 34561836
Drug Deliv Transl Res. 2021 Sep 24; doi: 10.1007/s13346-021-01070-w. Epub 2021 Sep 24.

Background Extending the lifespan of subcutaneous insulin administration sets and infusion pumps requires overcoming unreliable insulin delivery induced by dermal reactions. All commercially available insulin formulations contain insulin phenolic preservatives (IPP), which stabilize the insulin molecule but result in...

Cite
Kesserwan S, Mao L, Sharafieh R, et al. A pharmacological approach assessing the role of mast cells in insulin infusion site inflammation. Drug Deliv Transl Res. 2021;doi: 10.1007/s13346-021-01070-w.
Kesserwan, S., Mao, L., Sharafieh, R., Kreutzer, D. L., & Klueh, U. (2021). A pharmacological approach assessing the role of mast cells in insulin infusion site inflammation. Drug delivery and translational research, . https://doi.org/10.1007/s13346-021-01070-w
Kesserwan, Shereen, et al. "A pharmacological approach assessing the role of mast cells in insulin infusion site inflammation." Drug delivery and translational research vol. (2021). doi: https://doi.org/10.1007/s13346-021-01070-w
Kesserwan S, Mao L, Sharafieh R, Kreutzer DL, Klueh U. A pharmacological approach assessing the role of mast cells in insulin infusion site inflammation. Drug Deliv Transl Res. 2021 Sep 24; doi: 10.1007/s13346-021-01070-w. Epub 2021 Sep 24. PMID: 34561836.
Copy Download .nbib Format: NLM
Current concepts in ocular allergy.

Annals of allergy

Friedlaender MH.
PMID: 1859041
Ann Allergy. 1991 Jul;67(1):5-10, 13.

Ocular allergy is commonly encountered by the allergist, general physician, and ophthalmologist. Diagnosis can usually be made by history, especially a history of itching and an allergic background. The diagnosis can be confirmed by skin testing, in vitro testing,...

Cite
Friedlaender MH. Current concepts in ocular allergy. Ann Allergy. 1991;67(1):5-10, 13
Friedlaender, M. H. (1991). Current concepts in ocular allergy. Annals of allergy, 67(1), 5-10, 13.
Friedlaender, M H. "Current concepts in ocular allergy." Annals of allergy vol. 67,1 (1991): 5-10, 13.
Friedlaender MH. Current concepts in ocular allergy. Ann Allergy. 1991 Jul;67(1):5-10, 13. PMID: 1859041.
Copy Download .nbib Format: NLM
Effects of cromolyn sodium on isolated rat's trachea.

Allergy & rhinology (Providence, R.I.)

Lin YY, Chou YL, Chu YH, Wu CC, Wang JY, Wang HW.
PMID: 22852116
Allergy Rhinol (Providence). 2011 Apr;2(2):e46-50. doi: 10.2500/ar.2011.2.0015.

Cromolyn sodium (cromolyn) effectively inhibits both antigen- and exercise-induced asthma when used as an aerosol. Intranasal cromolyn is also recommended for preventing and treating allergic rhinitis. By inhibiting the degranulation of sensitized mast cells, cromolyn reduces the release of...

Cite
Lin YY, Chou YL, Chu YH, et al. Effects of cromolyn sodium on isolated rat's trachea. Allergy Rhinol (Providence). 2011;2(2):e46-50doi: 10.2500/ar.2011.2.0015.
Lin, Y. Y., Chou, Y. L., Chu, Y. H., Wu, C. C., Wang, J. Y., & Wang, H. W. (2011). Effects of cromolyn sodium on isolated rat's trachea. Allergy & rhinology (Providence, R.I.), 2(2), e46-50. https://doi.org/10.2500/ar.2011.2.0015
Lin, Yuan-Yung, et al. "Effects of cromolyn sodium on isolated rat's trachea." Allergy & rhinology (Providence, R.I.) vol. 2,2 (2011): e46-50. doi: https://doi.org/10.2500/ar.2011.2.0015
Lin YY, Chou YL, Chu YH, Wu CC, Wang JY, Wang HW. Effects of cromolyn sodium on isolated rat's trachea. Allergy Rhinol (Providence). 2011 Apr;2(2):e46-50. doi: 10.2500/ar.2011.2.0015. PMID: 22852116; PMCID: PMC3390115.
Copy Download .nbib Format: NLM
Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium.

Journal of pharmacy & bioallied sciences

Rakesh R, Anoop KR.
PMID: 23248569
J Pharm Bioallied Sci. 2012 Oct;4(4):333-40. doi: 10.4103/0975-7406.103274.

AIM: The current study was aimed to investigate the feasibility of transdermal delivery of cromolyn sodium using a novel lipid vesicular carrier, ethosomes.MATERIALS AND METHODS: Ethosomes of cromolyn sodium was prepared, optimized, and characterized for vesicle shape, vesicle size...

Cite
Rakesh R, Anoop KR. Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium. J Pharm Bioallied Sci. 2012;4(4):333-40doi: 10.4103/0975-7406.103274.
Rakesh, R., & Anoop, K. R. (2012). Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium. Journal of pharmacy & bioallied sciences, 4(4), 333-40. https://doi.org/10.4103/0975-7406.103274
Rakesh, R, and Anoop, K R. "Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium." Journal of pharmacy & bioallied sciences vol. 4,4 (2012): 333-40. doi: https://doi.org/10.4103/0975-7406.103274
Rakesh R, Anoop KR. Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium. J Pharm Bioallied Sci. 2012 Oct;4(4):333-40. doi: 10.4103/0975-7406.103274. PMID: 23248569; PMCID: PMC3523531.
Copy Download .nbib Format: NLM
Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis.

Current therapeutic research, clinical and experimental

Ciprandi G, Turner D, Gross RD.
PMID: 24764588
Curr Ther Res Clin Exp. 2004 Mar;65(2):186-99. doi: 10.1016/S0011-393X(04)90032-X.

BACKGROUND: It is estimated that >50% of medications have not been tested in children. Physicians need pediatric data to guide them in treating children. Olopatadine hydrochloride ophthalmic solution 0.1% is a topical antiallergic agent that is both an antihistamine...

Cite
Ciprandi G, Turner D, Gross RD. Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr Ther Res Clin Exp. 2004;65(2):186-99doi: 10.1016/S0011-393X(04)90032-X.
Ciprandi, G., Turner, D., & Gross, R. D. (2004). Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Current therapeutic research, clinical and experimental, 65(2), 186-99. https://doi.org/10.1016/S0011-393X(04)90032-X
Ciprandi, Giorgio, et al. "Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis." Current therapeutic research, clinical and experimental vol. 65,2 (2004): 186-99. doi: https://doi.org/10.1016/S0011-393X(04)90032-X
Ciprandi G, Turner D, Gross RD. Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr Ther Res Clin Exp. 2004 Mar;65(2):186-99. doi: 10.1016/S0011-393X(04)90032-X. PMID: 24764588; PMCID: PMC3997093.
Copy Download .nbib Format: NLM
Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer.

European clinical respiratory journal

Abd-Elaziz K, Oude Elberink H, Diamant Z.
PMID: 32944204
Eur Clin Respir J. 2020 Aug 20;7(1):1809083. doi: 10.1080/20018525.2020.1809083.

In 1960s, cromolyn sodium (CS) has been introduced as the first non-steroidal anti-inflammatory drug for the treatment of allergic and mast-cell driven diseases. Its applicability has been limited due to a poor bioavailability. Here we present pharmacokinetic data of...

Cite
Abd-Elaziz K, Oude Elberink H, Diamant Z. Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer. Eur Clin Respir J. 2020;7(1):1809083doi: 10.1080/20018525.2020.1809083.
Abd-Elaziz, K., Oude Elberink, H., & Diamant, Z. (2020). Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer. European clinical respiratory journal, 7(1), 1809083. https://doi.org/10.1080/20018525.2020.1809083
Abd-Elaziz, Khalid, et al. "Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer." European clinical respiratory journal vol. 7,1 (2020): 1809083. doi: https://doi.org/10.1080/20018525.2020.1809083
Abd-Elaziz K, Oude Elberink H, Diamant Z. Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer. Eur Clin Respir J. 2020 Aug 20;7(1):1809083. doi: 10.1080/20018525.2020.1809083. PMID: 32944204; PMCID: PMC7480408.
Copy Download .nbib Format: NLM
Optimal use of topical agents for allergic conjunctivitis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Mösges R, Hassan HA, Wenzel MR.
PMID: 18020517
BioDrugs. 1997 Oct;8(4):250-64. doi: 10.2165/00063030-199708040-00002.

In recent years, there has been renewed interest in the topical treatment of allergic conjunctivitis, a disorder that is involved in the common red-eye syndrome. Topical treatment for rapid relief of symptoms is most often preferred by the patient,...

Cite
Mösges R, Hassan HA, Wenzel MR. Optimal use of topical agents for allergic conjunctivitis. BioDrugs. 1997;8(4):250-64doi: 10.2165/00063030-199708040-00002.
Mösges, R., Hassan, H. A., & Wenzel, M. R. (1997). Optimal use of topical agents for allergic conjunctivitis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 8(4), 250-64. https://doi.org/10.2165/00063030-199708040-00002
Mösges, R, et al. "Optimal use of topical agents for allergic conjunctivitis." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 8,4 (1997): 250-64. doi: https://doi.org/10.2165/00063030-199708040-00002
Mösges R, Hassan HA, Wenzel MR. Optimal use of topical agents for allergic conjunctivitis. BioDrugs. 1997 Oct;8(4):250-64. doi: 10.2165/00063030-199708040-00002. PMID: 18020517.
Copy Download .nbib Format: NLM
Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery.

Journal of young pharmacists : JYP

Shastri D, Patel L, Parikh R.
PMID: 21264112
J Young Pharm. 2010 Apr;2(2):116-20. doi: 10.4103/0975-1483.63144.

The present work describes the formulation development of ophthalmic in situ gelling system using thermo-reversible gelling polymer, i.e. Pluronic F 127 (PF127). Because of high concentration (20 to 25%w/v) of this polymer required for in situ gelation causes irritation...

Cite
Shastri D, Patel L, Parikh R. Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. J Young Pharm. 2010;2(2):116-20doi: 10.4103/0975-1483.63144.
Shastri, D., Patel, L., & Parikh, R. (2010). Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. Journal of young pharmacists : JYP, 2(2), 116-20. https://doi.org/10.4103/0975-1483.63144
Shastri, Dh, et al. "Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery." Journal of young pharmacists : JYP vol. 2,2 (2010): 116-20. doi: https://doi.org/10.4103/0975-1483.63144
Shastri D, Patel L, Parikh R. Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. J Young Pharm. 2010 Apr;2(2):116-20. doi: 10.4103/0975-1483.63144. PMID: 21264112; PMCID: PMC3021684.
Copy Download .nbib Format: NLM
Physical Activity and the Asthmatic.

The Physician and sportsmedicine

Morton AR, Fitch KD, Hahn AG.
PMID: 27430135
Phys Sportsmed. 1981 Mar;9(3):50-64. doi: 10.1080/00913847.1981.11711031.

In brief: Recent studies suggest that avoiding exercise is unwarranted and detrimental for asthmatics. Although exercise provokes bronchospasm in most asthmatics, the severity of exercise-induced asthma can be reduced by several factors: control of exercise duration; less intense, intermittent...

Cite
Morton AR, Fitch KD, Hahn AG. Physical Activity and the Asthmatic. Phys Sportsmed. 1981;9(3):50-64doi: 10.1080/00913847.1981.11711031.
Morton, A. R., Fitch, K. D., & Hahn, A. G. (1981). Physical Activity and the Asthmatic. The Physician and sportsmedicine, 9(3), 50-64. https://doi.org/10.1080/00913847.1981.11711031
Morton, A R, et al. "Physical Activity and the Asthmatic." The Physician and sportsmedicine vol. 9,3 (1981): 50-64. doi: https://doi.org/10.1080/00913847.1981.11711031
Morton AR, Fitch KD, Hahn AG. Physical Activity and the Asthmatic. Phys Sportsmed. 1981 Mar;9(3):50-64. doi: 10.1080/00913847.1981.11711031. PMID: 27430135.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries